Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature.
Anti-nuclear matrix protein 2 (NXP2) antibody
Hemophagocytic syndrome
Juvenile dermatomyositis
Macrophage activation syndrome
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
21 Sep 2023
21 Sep 2023
Historique:
received:
22
06
2023
accepted:
06
09
2023
medline:
25
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
Macrophage activation syndrome (MAS) is a severe and life-threatening syndrome associated with autoimmune diseases. The coexistence of MAS and juvenile dermatomyositis (JDM) is not well reported. This report describes a case of JDM with MAS and summarizes the clinical characteristics and prognosis of MAS in patients with JDM. The patient was a 15-year-old female with JDM, presenting with heliotrope rash, muscle weakness, increased muscle enzyme, anti-nuclear matrix protein 2 (NXP2) antibody, and muscle biopsy consistent with JDM. The patient developed fever, cytopenia, and hyperferritinemia three months after the first manifestations. Hemophagocytosis was found in the bone marrow. The final diagnosis was JDM combined with MAS. Despite intensive treatment, the patient died of MAS. By reviewing the literature, we found 17 similar cases. Together with the present case, 18 patients were identified, the median age of disease onset was 13.5 years, and male to female ratio was 1.25: 1. Nine out of 16 (56.3%) patients were complicated with interstitial lung disease (ILD). The median time interval between JDM onset and MAS diagnosis was 9 weeks. At the onset of MAS, all (100%) patients had elevated levels of ferritin and serum liver enzymes. Among 18 patients, 14 (77.8%) had fever, 14/17 (82.4%) had cytopenia, 11/11 (100%) had hepatosplenomegaly, and 13/14 (92.9%) had hemophagocytosis. Five (27.8%) patients showed central nervous system (CNS) involvement. The mortality of MAS rate of in patients with JDM was 16.7%, despite various treatment methods. . The coexistence of JDM and MAS is underestimated with increased mortality. Hepatosplenomegaly and increased serum levels of ferritin in patients with JDM should raise clinical suspicion for MAS.
Sections du résumé
BACKGROUND
BACKGROUND
Macrophage activation syndrome (MAS) is a severe and life-threatening syndrome associated with autoimmune diseases. The coexistence of MAS and juvenile dermatomyositis (JDM) is not well reported. This report describes a case of JDM with MAS and summarizes the clinical characteristics and prognosis of MAS in patients with JDM.
CASE PRESENTATION
METHODS
The patient was a 15-year-old female with JDM, presenting with heliotrope rash, muscle weakness, increased muscle enzyme, anti-nuclear matrix protein 2 (NXP2) antibody, and muscle biopsy consistent with JDM. The patient developed fever, cytopenia, and hyperferritinemia three months after the first manifestations. Hemophagocytosis was found in the bone marrow. The final diagnosis was JDM combined with MAS. Despite intensive treatment, the patient died of MAS. By reviewing the literature, we found 17 similar cases. Together with the present case, 18 patients were identified, the median age of disease onset was 13.5 years, and male to female ratio was 1.25: 1. Nine out of 16 (56.3%) patients were complicated with interstitial lung disease (ILD). The median time interval between JDM onset and MAS diagnosis was 9 weeks. At the onset of MAS, all (100%) patients had elevated levels of ferritin and serum liver enzymes. Among 18 patients, 14 (77.8%) had fever, 14/17 (82.4%) had cytopenia, 11/11 (100%) had hepatosplenomegaly, and 13/14 (92.9%) had hemophagocytosis. Five (27.8%) patients showed central nervous system (CNS) involvement. The mortality of MAS rate of in patients with JDM was 16.7%, despite various treatment methods.
CONCLUSION
CONCLUSIONS
. The coexistence of JDM and MAS is underestimated with increased mortality. Hepatosplenomegaly and increased serum levels of ferritin in patients with JDM should raise clinical suspicion for MAS.
Identifiants
pubmed: 37735702
doi: 10.1186/s12969-023-00893-w
pii: 10.1186/s12969-023-00893-w
pmc: PMC10515226
doi:
Substances chimiques
Ferritins
9007-73-2
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Subventions
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-NHLHCRF-YS-02
Organisme : Elite Medical Professionals Project of China-Japan Friendship Hospital
ID : NO.ZRJY2023-GG02
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ther Adv Chronic Dis. 2022 May 13;13:20406223221098128
pubmed: 35586303
Mod Rheumatol. 2013 Mar;23(2):386-92
pubmed: 22576792
Mod Rheumatol. 2020 May;30(3):411-423
pubmed: 31955618
J Rheumatol. 2008 Sep;35(9):1838-41
pubmed: 18634143
J Rheumatol. 2004 May;31(5):1014-5; author reply 1015
pubmed: 15124278
Pediatr Ann. 2017 Aug 1;46(8):e309-e313
pubmed: 28806468
Best Pract Res Clin Rheumatol. 2017 Aug;31(4):535-557
pubmed: 29773272
Front Pharmacol. 2021 Mar 16;12:635654
pubmed: 33815117
J Rheumatol. 2015 Jun;42(6):979-87
pubmed: 25877505
Indian J Pediatr. 2016 Mar;83(3):248-53
pubmed: 26400031
Mod Rheumatol Case Rep. 2023 Jun 19;7(2):404-409
pubmed: 36416547
J Rheumatol. 2018 Jul;45(7):947-955
pubmed: 29657141
Clin Vaccine Immunol. 2011 Apr;18(4):609-14
pubmed: 21270283
Rheumatol Int. 2020 Jul;40(7):1151-1162
pubmed: 32356114
Indian Pediatr. 2022 Sep 15;59(9):725-726
pubmed: 36101954
Clin Immunol. 2009 Jul;132(1):10-8
pubmed: 19297252
Acta Paediatr. 2000 May;89(5):617-9
pubmed: 10852205
J Med Case Rep. 2016 Aug 02;10:212
pubmed: 27484255
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Clin Rheumatol. 2013 Jun;32(6):899-904
pubmed: 23483294
Scand J Rheumatol. 2006 Jan-Feb;35(1):79-80
pubmed: 16467051
Pediatr Rheumatol Online J. 2022 Feb 22;20(1):16
pubmed: 35193600
Rheumatol Int. 2019 May;39(5):901-909
pubmed: 30790016
Diagnostics (Basel). 2021 Dec 21;12(1):
pubmed: 35054173
Pediatr Pulmonol. 2013 Oct;48(10):1016-25
pubmed: 23281200
Scand J Rheumatol. 2014;43(2):171-3
pubmed: 24588361
Rheumatology (Oxford). 2014 Dec;53(12):2204-8
pubmed: 24987158
An Pediatr (Barc). 2012 Jul;77(1):47-50
pubmed: 22342516
Arthritis Rheum. 2009 Jun;60(6):1807-14
pubmed: 19479859
Pediatr Rheumatol Online J. 2015 Nov 18;13:49
pubmed: 26581448
Autoimmun Rev. 2014 Nov;13(11):1142-8
pubmed: 24879966
Rheumatol Int. 2020 May;40(5):695-702
pubmed: 31529231
Arthritis Rheumatol. 2020 Feb;72(2):326-334
pubmed: 31513353
Paediatr Child Health. 2018 Jul;23(4):241-244
pubmed: 30038528
Rheumatology (Oxford). 2012 Sep;51(9):1563-70
pubmed: 22589330
J Pediatr Hematol Oncol. 2009 Feb;31(2):81-4
pubmed: 19194188
Pediatr Rheumatol Online J. 2015 Dec 03;13:55
pubmed: 26634252
Semin Arthritis Rheum. 2015 Feb;44(4):405-10
pubmed: 25200945